1. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-60.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933-8.
3. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353: 1167-73.
4. Caprini JA, Glase CJ, Anderson CB, Hathaway K. Laboratory markers in the diagnosis of venous thromboembolism. Circulation. 2004;109:I4-8.
5. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995;85:3518-23.
6. van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, et al. Factor V Leiden (FV R506Q) in families with inherited anti-thrombin deficiency. Thromb Haemost. 1996;75:417-21.
7. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031-5.
8. Tirado I, Mateo J, Soria JM, Oliver A, Borrell M, Coll I, et al. Contribution of prothrombin 20210A allele and factor V Leiden mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies. Haematologica. 2001;86:1200-8.
9. Castaman G, Tosetto A, Cappellari A, Ruggeri M, Rodeghiero F. The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency. Blood Coagul Fibrinolysis. 2000;11:321-6.
10. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJ, Pabinger I, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost. 2005;3:459-64.
11. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol. 1996;143:1257-65.
12. Brouwer JL, Veeger NJ, van der Schaaf W, Kluin-Nelemans HC, van der Meer J. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol. 2005;128:703-10.
13. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-7.
14. Danneberg J, Abbes AP, Bruggeman BJ, Engel H, Gerrits J, Martens A. Reliable genotyping of the G-20210-A mutation of coagulation factor II (pro-thrombin). Clin Chem. 1998;44:349-51.
15. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost. 1991;65:320-2.
16. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43-52.
17. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-62.
18. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott–Raven; 1998:247-52.
19. van den Belt AG, Prins MH, Huisman MV, Hirsh J. Familial thrombophilia: a review analysis. Clin Appl Thromb Hemost. 1996;2:227-36.
20. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81:198-202.
21. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Casta-man G, et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 1994;72:352-8.
22. Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittmann E, Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost. 1994;71:441-5.
23. Sanson BJ, Simioni P, Tormene D, Moia M, Friederich PW, Huisman V, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood. 1999;94:3702-6.
24. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-4.
25. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706-8.
26. Rosendaal FR, Heijboer H, Brie¨t E, Bu¨ller HR, Brandjes DP, de Bruin K, et al. Mortality in hereditary antithrombin-III deficiency—1830 to 1989. Lancet. 1991;337:260-2.
27. Allaart CF, Rosendaal FR, Noteboom WM, Vandenbroucke JP, Brie¨t E. Survival in families with hereditary protein C deficiency, 1820 to 1993. BMJ. 1995;311:910-3.
Traducción y resumen objetivo: Dra. Marta Papponetti. Esp. Medicinta Interna. Docente Aut. UBA. Editora Responsable Med. Interna de Intramed.